Monopar Therapeutics Inc. (MNPR) Total liabilities 2016–2025
Monopar Therapeutics Inc. (MNPR) total liabilities at each fiscal year-end, per SEC filings.
$2.9MFY2025 · since FY2016: $64,510 → $2.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.9M | -45.0% |
| FY2024 | $5.3M | — |
| FY2019 | $724,165 | +81.2% |
| FY2018 | $399,551 | +28.1% |
| FY2017 | $311,867 | +383.4% |
| FY2016 | $64,510 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More MNPR financial trends
MNPR RevenueMNPR Net incomeMNPR Net marginMNPR Gross profitMNPR Gross marginMNPR Operating incomeMNPR Operating marginMNPR Operating cash flowMNPR Free cash flowMNPR Capital expendituresMNPR Return on equityMNPR Stock buybacksMNPR Dividends paidMNPR Total assetsMNPR Shareholders’ equityMNPR overview →